Search

Your search keyword '"Bielack, S."' showing total 35 results

Search Constraints

Start Over You searched for: Author "Bielack, S." Remove constraint Author: "Bielack, S." Journal annals of oncology Remove constraint Journal: annals of oncology
35 results on '"Bielack, S."'

Search Results

1. Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

3. Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

4. Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

5. Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

6. Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

7. Osteosarcoma of the mobile spine

11. 534P Larotrectinib in non-CNS TRK fusion cancer patients: Outcomes by prior therapy and performance status

14. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment†

16. The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols

22. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment†

23. Adolescents and young adults with cancer care in Asia: The joint ESMO/SIOPE/SIOP ASIA survey

24. Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach

25. Corrections to “Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”

26. Corrections to “Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”

28. Phase 1/2 study of the selective TRK inhibitor larotrectinib, in pediatric patients with cancer

29. Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.

32. High-grade bone sarcomas with synchronous metastases in patients older than 40. Results of the European Bone over 40: Sarcoma Study (EURO.B.O.S.S.)

Catalog

Books, media, physical & digital resources